Rhabdoid morphology in gastrointestinal stromal tumours (GISTs) is associated with PDGFRA mutations but does not imply aggressive behaviour

Histopathology

Volumn 64, Issue 3, 2014, Pages 421-430

  Schaefer, Inga Marie ^a,b   Ströbel, Philipp ^b   Cameron, Silke ^b   Beham, Alexander ^b   Otto, Claudia ^c   Schildhaus, Hans Ulrich ^b,d   Agaimy, Abbas ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

CGH; Gastric; GIST; PDGFRA mutation; Rhabdoid; SDH; SMARCB1

Indexed keywords

CD34 ANTIGEN; DESMIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR; SUCCINATE DEHYDROGENASE; VIMENTIN;

ADULT; AGGRESSIVENESS; ARTICLE; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE FREE SURVIVAL; EXON; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; RHABDOID TUMOR;

CGH; GASTRIC; GIST; PDGFRA MUTATION; RHABDOID; SDH; SMARCB1;

ADULT; CHROMOSOMAL PROTEINS, NON-HISTONE; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 84892440242     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12265     Document Type: Article

References (39)

1. Baschinsky DY, Niemann TH, Eaton LA, Frankel WL. Malignant mixed Mullerian tumor with rhabdoid features: a report of two cases and a review of the literature. Gynecol. Oncol. 1999; 73; 145-150.
2. Richmond JA, Mount SL, Schwarz JE. Gastrointestinal stromal tumor of the stomach with rhabdoid phenotype: immunohistochemical, ultrastructural, and immunoelectron microscopic evaluation. Ultrastruct. Pathol. 2004; 28; 165-170.
3. Perry A, Scheithauer BW, Stafford SL, Abell-Aleff PC, Meyer FB. 'Rhabdoid' meningioma: an aggressive variant. Am. J. Surg. Pathol. 1998; 22; 1482-1490.
4. Oda Y, Tsuneyoshi M. Extrarenal rhabdoid tumors of soft tissue: clinicopathological and molecular genetic review and distinction from other soft-tissue sarcomas with rhabdoid features. Pathol. Int. 2006; 56; 287-295.
5. Parham DM, Weeks DA, Beckwith JB. The clinicopathologic spectrum of putative extrarenal rhabdoid tumors. An analysis of 42 cases studied with immunohistochemistry or electron microscopy. Am. J. Surg. Pathol. 1994; 18; 1010-1029.
6. Ogino S, Ro TY, Redline RW. Malignant rhabdoid tumor: a phenotype? An entity?-A controversy revisited. Adv. Anat. Pathol. 2000; 7; 181-190.
7. Biegel JA, Tan L, Zhang F, Wainwright L, Russo P, Rorke LB. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin. Cancer Res. 2002; 8; 3461-3467.
8. Bourdeaut F, Freneaux P, Thuille B et al. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J. Pathol. 2007; 211; 323-330.
9. Vries RG, Bezrookove V, Zuijderduijn LM et al. Cancer-associated mutations in chromatin remodeler hSNF5 promote chromosomal instability by compromising the mitotic checkpoint. Genes Dev. 2005; 19; 665-670.
10. Sevenet N, Lellouch-Tubiana A, Schofield D et al. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum. Mol. Genet. 1999; 8; 2359-2368.
11. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 2004; 22; 3813-3825.
12. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin. Diagn. Pathol. 2006; 23; 70-83.
13. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch. Pathol. Lab. Med. 2006; 130; 1466-1478.
14. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab. Invest. 2004; 84; 874-883.
15. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003; 21; 4342-4349.
16. Debiec-Rychter M, Wasag B, Stul M et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J. Pathol. 2004; 202; 430-438.
17. Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am. J. Surg. Pathol. 2011; 35; 1712-1721.
18. Janeway KA, Kim SY, Lodish M et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc. Natl Acad. Sci. USA 2011; 108; 314-318.
19. Miettinen M, Killian JK, Wang ZF et al. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am. J. Surg. Pathol. 2013; 37; 234-240.
20. Wagner AJ, Remillard SP, Zhang YX, Doyle LA, George S, Hornick JL. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod. Pathol. 2013; 26; 289-294.
21. Wardelmann E, Hrychyk A, Merkelbach-Bruse S et al. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J. Mol. Diagn. 2004; 6; 197-204.
22. Hanson JA, Trent JC, Yang D, Cooper K. Small-intestinal rhabdoid gastrointestinal stromal tumor (GIST): mutation analysis and clinical implications of a rare morphological variant. Int. J. Surg. Pathol. 2011; 19; 653-657.
23. Kwon JE, Kang HJ, Kim SH et al. Pathological characteristics of gastrointestinal stromal tumours with PDGFRA mutations. Pathology 2009; 41; 544-554.
24. Daum O, Grossmann P, Vanecek T, Sima R, Mukensnabl P, Michal M. Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Ann. Diagn. Pathol. 2007; 11; 27-33.
25. Tazawa K, Tsukada K, Makuuchi H, Tsutsumi Y. An immunohistochemical and clinicopathological study of gastrointestinal stromal tumors. Pathol. Int. 1999; 49; 786-798.
26. Lee JR, Joshi V, Griffin JW Jr, Lasota J, Miettinen M. Gastrointestinal autonomic nerve tumor: immunohistochemical and molecular identity with gastrointestinal stromal tumor. Am. J. Surg. Pathol. 2001; 25; 979-987.
27. Gunawan B, von Heydebreck A, Sander B et al. An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications. J. Pathol. 2007; 211; 463-470.
28. Gunawan B, Schulten HJ, von Heydebreck A et al. Site-independent prognostic value of chromosome 9q loss in primary gastrointestinal stromal tumours. J. Pathol. 2004; 202; 421-429.
29. Chen Y, Tzeng CC, Liou CP, Chang MY, Li CF, Lin CN. Biological significance of chromosomal imbalance aberrations in gastrointestinal stromal tumors. J. Biomed. Sci. 2004; 11; 65-71.
30. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res. 2000; 60; 3899-3903.
31. Wozniak A, Sciot R, Guillou L et al. Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosom. Cancer 2007; 46; 261-276.
32. Gunawan B, Bergmann F, Hoer J et al. Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. Hum. Pathol. 2002; 33; 316-321.
33. Haller F, Gunawan B, von Heydebreck A et al. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clin. Cancer Res. 2005; 11; 6589-6597.
34. Corless CL, Schroeder A, Griffith D et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 2005; 23; 5357-5364.
35. Schaefer IM, Delfs C, Cameron S et al. Chromosomal aberrations in primary PDGFRA-mutated gastrointestinal stromal tumors (GISTs). Hum. Pathol. 2013; pii: S0046-8177(13)00346-8. doi: 10.1016/j.humpath.2013.05.027.
36. Lasota J, Stachura J, Miettinen M. GISTs with PDGFRA exon 14 mutations represent a subset of clinically favorable gastric tumors with epithelioid morphology. Lab. Invest. 2006; 86; 94-100.
37. Doyle LA, Nelson D, Heinrich MC, Corless CL, Hornick JL. Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. Histopathology 2012; 61; 801-809.
38. Yamamoto H, Kohashi K, Tsuneyoshi M, Oda Y. Heterozygosity loss at 22q and lack of INI1 gene mutation in gastrointestinal stromal tumor. Pathobiology 2011; 78; 132-139.
39. Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am. J. Surg. Pathol. 2009; 33; 218-226.